Introduction: Duvelisib, a first in class, oral, dual PI3 k-delta/gamma inhibitor recently received FDA approval for previously treated CLL (chronic lymphocytic leukemia)/SLL (small lymphocytic lymphoma) and follicular lymphoma. Data coming from the phase III ‘DUO’ trial, in fact, showed a superior progression-free survival (PFS) in CLL patients treated with duvelisib compared to ofatumumab Areas covered: This review provides analysis of the mechanism of action of duvelisib and includes the rationale for the use of double inhibition. The authors also give their clinical experience with duvelisib. Overall, despite the high efficacy of the drug, some concern remains on duvelisib-related adverse events leading to treatment interruption in a significant proportion of patients. Expert opinion: Considering the unmet need of salvage therapies in patients failing BTK and/or Bcl2 inhibitors, treatment with duvelisib represents a new valid option in the CLL therapeutic armamentarium. Therefore, the correct management of adverse events with early treatment suspension, dose reductions and prompt supportive treatment could help to manage treatment, thus improving patient outcome. Finally, the association of duvelisib with other targeted therapies, such as ibrutinib or venetoclax, could allow clinicians to capitalize on the synergistic activity of these agents.

Anna Maria, F., Alessandra, T., Marina, D., Giulia, Z., Cairoli, R., Marco, M. (2020). Duvelisib for the treatment of chronic lymphocytic leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 21(11), 1299-1309 [10.1080/14656566.2020.1751123].

Duvelisib for the treatment of chronic lymphocytic leukemia

Cairoli R
Penultimo
;
2020

Abstract

Introduction: Duvelisib, a first in class, oral, dual PI3 k-delta/gamma inhibitor recently received FDA approval for previously treated CLL (chronic lymphocytic leukemia)/SLL (small lymphocytic lymphoma) and follicular lymphoma. Data coming from the phase III ‘DUO’ trial, in fact, showed a superior progression-free survival (PFS) in CLL patients treated with duvelisib compared to ofatumumab Areas covered: This review provides analysis of the mechanism of action of duvelisib and includes the rationale for the use of double inhibition. The authors also give their clinical experience with duvelisib. Overall, despite the high efficacy of the drug, some concern remains on duvelisib-related adverse events leading to treatment interruption in a significant proportion of patients. Expert opinion: Considering the unmet need of salvage therapies in patients failing BTK and/or Bcl2 inhibitors, treatment with duvelisib represents a new valid option in the CLL therapeutic armamentarium. Therefore, the correct management of adverse events with early treatment suspension, dose reductions and prompt supportive treatment could help to manage treatment, thus improving patient outcome. Finally, the association of duvelisib with other targeted therapies, such as ibrutinib or venetoclax, could allow clinicians to capitalize on the synergistic activity of these agents.
Articolo in rivista - Articolo scientifico
chronic lymphocytic leukemia; cll; dual inhibition; Duvelisib; ipi-145; novel agents; pi3k; relapsed; targeted agents;
English
2020
21
11
1299
1309
reserved
Anna Maria, F., Alessandra, T., Marina, D., Giulia, Z., Cairoli, R., Marco, M. (2020). Duvelisib for the treatment of chronic lymphocytic leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 21(11), 1299-1309 [10.1080/14656566.2020.1751123].
File in questo prodotto:
File Dimensione Formato  
Frustaci-2020-Exp Opinion Pharmacother-VoR.pdf

Solo gestori archivio

Descrizione: Drug evaluation
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/405077
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
Social impact